Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Hinge Health (HNGE) Current Deferred Revenue (2023 - 2025)

Hinge Health (HNGE) has disclosed Current Deferred Revenue for 3 consecutive years, with $300.9 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 38.24% to $300.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $300.9 million through Dec 2025, up 38.24% year-over-year, with the annual reading at $300.9 million for FY2025, 38.24% up from the prior year.
  • Current Deferred Revenue hit $300.9 million in Q4 2025 for Hinge Health, roughly flat from $299.7 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $300.9 million in Q4 2025 to a low of $140.5 million in Q4 2023.
  • Historically, Current Deferred Revenue has averaged $233.0 million across 3 years, with a median of $217.6 million in 2024.
  • Biggest five-year swings in Current Deferred Revenue: surged 54.93% in 2024 and later soared 38.24% in 2025.
  • Year by year, Current Deferred Revenue stood at $140.5 million in 2023, then surged by 54.93% to $217.6 million in 2024, then skyrocketed by 38.24% to $300.9 million in 2025.
  • Business Quant data shows Current Deferred Revenue for HNGE at $300.9 million in Q4 2025, $299.7 million in Q3 2025, and $275.1 million in Q2 2025.